KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Neogenomics (NEO) Equity Ratio (2016 - 2025)

Historic Equity Ratio for Neogenomics (NEO) over the last 17 years, with Q4 2025 value amounting to 0.62.

  • Neogenomics' Equity Ratio rose 1167.8% to 0.62 in Q4 2025 from the same period last year, while for Dec 2025 it was 0.62, marking a year-over-year increase of 1167.8%. This contributed to the annual value of 0.62 for FY2025, which is 1167.8% up from last year.
  • As of Q4 2025, Neogenomics' Equity Ratio stood at 0.62, which was up 1167.8% from 0.61 recorded in Q3 2025.
  • Neogenomics' 5-year Equity Ratio high stood at 0.62 for Q4 2025, and its period low was 0.55 during Q4 2024.
  • Over the past 5 years, Neogenomics' median Equity Ratio value was 0.57 (recorded in 2022), while the average stood at 0.58.
  • As far as peak fluctuations go, Neogenomics' Equity Ratio tumbled by 9747.3% in 2021, and later soared by 1167.8% in 2025.
  • Quarter analysis of 5 years shows Neogenomics' Equity Ratio stood at 0.59 in 2021, then dropped by 3.23% to 0.57 in 2022, then dropped by 2.36% to 0.56 in 2023, then dropped by 1.64% to 0.55 in 2024, then grew by 11.68% to 0.62 in 2025.
  • Its last three reported values are 0.62 in Q4 2025, 0.61 for Q3 2025, and 0.61 during Q2 2025.